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Abstract 
The coexistence of lung cancer and multiple myeloma (MM) is rare. A search of the 
English literature revealed only 5 case reports to date. We describe a case of MM that 
presented in a 78-year-old lung cancer patient after 20 months of treatment with 
gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor. We also review 
previously reported cases of concurrent development of lung cancer and MM. 
 
Introduction 
Multiple myeloma (MM) is a rare post-germinal center B-cell malignancy. The 
coexistence of MM and lung cancer is uncommon. A search of the English literature for 
synchronous cases of lung cancer and MM revealed only 5 cases (table 1) [1–5]. 
Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) 
used to treat non-small cell lung carcinoma [6]. EGFR is expressed in a wide range of 
solid tumors, as well as in malignant myeloma cells [7]. Binding of the ligand to EGFR 
activates tyrosine kinase activity in the intracellular domain, leading to the initiation of 
signal transduction cascades involved in malignant cell proliferation and survival. Small 
molecule tyrosine kinase inhibitors (gefitinib, erlotinib) and an EGFR-specific antibody 
(cetuximab) were developed as first generation anti-EGFR therapies [6].  
We describe a case of MM that presented in a lung cancer patient who was treated with 
gefitinib for 20 months. To our knowledge, this is the first such case reported in the  
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literature. Previous cases of concurrent development of lung cancer and MM are also 
reviewed. 
Case Report 
A 78-year-old male presented to our pulmonology department for a workup of a right lung nodule 
(fig. 1) and right supraclavicular lymph node swelling (fig. 2). The patient was diagnosed with stage IV 
lung adenocarcinoma (EGFR mutation-positive) based on supraclavicular lymph node biopsy. Gefitinib 
therapy was initiated at 250 mg/day for 3 months. The dose of gefitinib had to be reduced to 250 mg 
every other day due to hepatotoxicity, but it was continued for 17 months. Gefitinib treatment 
successfully controlled the progression of the tumor and the patient maintained excellent functional 
status throughout the course of treatment.  
Twenty months after initiation of the gefitinib therapy, rapid progression of the lung tumor was 
noted with a mild decrease in white blood cells, red blood cells, and platelet count. It was initially 
supposed that this was due to the progression of adenocarcinoma of the lung and the patient was 
admitted for chemotherapy. He received carboplatin, paclitaxel, bevacizumab, and supportive therapy 
with granulocyte colony stimulating factor. After the first course of chemotherapy, the patient was 
restaged and the tumor showed a partial response. The patient continued to have pancytopenia after 
chemotherapy, which required frequent blood transfusions and supportive therapy. Therefore, he was 
referred to a hematologist for further evaluation.  
Laboratory results revealed: hemoglobin 5.7 g/dl, white blood cells 2,900/μl, and platelets 20,000/μl. 
Bone marrow aspiration showed plasma cell infiltration (84.8%). Serum immunoelectrophoresis showed 
monoclonal gammopathy with IgG λ protein and Bence-Jones λ protein, and urinalysis was also positive 
for Bence-Jones λ protein. Serum immunoelectrophoresis also revealed a decrease in albumin and beta 
globulin (41.8 and 6.4%, respectively) and an increase in gamma globulin (42.3%). Flow cytometric 
immunophenotyping indicated that plasma cells, as gated by bright expression of CD 38 and CD 138, 
were negative for CD 19, CD 56, CD 49e, and MPC 1. Karyotyping was abnormal and showed the 
following: 53, XY, +add(3)(q21), +5, +6, +7, +9, –13, +18, +21.  
Additional laboratory work revealed: β2-microglobulin 6.0 mg/l, albumin 2.4 mg/dl, Ca 11.1 mg/dl, 
Cr 1.34, IgG 3.6 g/dl, IgA 0.018 g/dl, and IgM 0.010 g/dl. No bone lesions were detected on skeletal 
survey. Diagnostic thoracentesis demonstrated an infiltration of plasma cells in the pleural fluid, which 
was confirmed by flow cytometry analysis. Thus, the diagnosis of MM (Durie Salmon IIIA, ISS III, 
SWOG III) was made in coexistence with stage IV lung adenocarcinoma. Conservative treatment with 
moderate doses of steroids and bortezomib was instituted. Despite partial remission of disease, the 
patient’s clinical course deteriorated and he died 2 weeks after admission to the hematology service. 
Review of the Literature 
Table 1 shows cases of synchronous lung cancer and MM reported in the English 
literature. All patients were male with a median age of 63 years (range 51–78). Four cases 
were diagnosed simultaneously during diagnostic workup for the initially diagnosed 
tumor. Marinopoulos et al. [4] reported a case of MM developing 6 months after 
initiation of chemotherapy for lung cancer. The histology of lung cancer was variable, and 
included 2 cases of adenocarcinoma, 2 cases of squamous cell carcinoma, and 1 case of 
small cell lung carcinoma. The myeloma isotype was IgG in all patients. 
Discussion 
It is difficult to determine whether synchronous MM and lung cancer occurred by 
chance, or if there is an association between the two tumors. Multiple primary cancers in  
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the same individual could reflect the influence of antecedent cancer therapy, as well as 
shared etiologic factors such as environmental exposure, genetic susceptibility, lifestyle 
choices, and the combinations of effects [8].  
Common environmental factors for lung cancer and MM include ionizing radiation 
and pesticides [9–11]. Several case reports of familial MM observed BRCA-1, BRCA-2, 
and p16 mutations in those families, suggesting that there may be a genetic predisposition 
[12]. When the development of lung cancer precedes MM or vice versa, it is possible that 
the antecedent cancer of the first tumor contributed to the development of the second 
tumor. While Marinopoulos et al. [4] reported a case of MM developing after the 
initiation of chemotherapy for lung cancer, a thorough search of the literature did not 
find any cases of MM in association with gefitinib. 
The etiology of the synchronous cancer occurrence in our patient is unclear, however, 
he had a strong family history of cancer (his father had pancreatic cancer and his mother 
had esophageal cancer). Being a nonsmoker and office worker by profession, no clear 
environmental exposure could be identified. Moreover, he did not have a history of 
chronic inflammatory disease.  
Mahtouk et al. [7] reported that EGFR is expressed on malignant plasma cells of MM 
and on cells of the MM microenvironment. It has been shown that inhibition of EGFR-
ligand signaling potentiates dexamethasone-induced MM cell apoptosis [13]. Currently, 
the safety and efficacy of cetuximab, an EGFR-specific antibody, is being evaluated for 
relapsed MM in a phase II study (ClinicalTrials.gov identifier: NCT00368121). 
Stabilization of relapsed MM with cetuximab treatment has also been reported [14]. 
Development of MM in the setting of prolonged EGFR inhibition as in our case is 
interesting in view of recent reports suggesting a role for EGFR inhibitors in refractory 
MM therapy. Although an EGFR mutation was confirmed via metastatic lymph node 
biopsy in our patient, the status of EGFR expression or if EGFR mutation was present in 
myeloma cells is unclear. Whether or not the presence of EGFR mutation determination 
would be useful in defining subsets of MM that are responsive to anti-EGFR therapy, as in 
the case of non-small cell carcinoma, remains to be investigated. 
There is no clear consensus on the treatment regimen for synchronous MM and lung 
cancer due to the extreme rarity of the combination. In previously reported cases, 
treatment was directed to the malignancy that was more advanced or the malignancy that 
carried a poorer prognosis. Several chemotherapeutic agents (cisplatin, docetaxel, 
vinorelbine, and topotecan) used in lung cancer treatment are sometimes included in MM 
treatment regimens as well [4]. In our patient, steroids and bortezomib were used. 
Bortezomib, a small molecule proteasome inhibitor, has activity both in MM and lung 
cancer. A phase II trial of this agent reported modest single-agent activity in patients with 
relapsed or refractory advanced non-small cell lung carcinoma [15]. 
In summary, we present a case of MM that developed in the setting of prolonged 
gefitinib treatment for lung cancer. Much is still unknown about the role of EGFR in MM 
and further studies are warranted. Currently, there are no reports associating gefitinib 
with the development of MM, but caution should be used in determining the long-term 
side effects of this relatively new drug. 
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Table 1. Case reports of concurrent MM and lung cancer characteristics 
Age MM  Lung  cancer       Reference Sex 
MM  
dx 
lung  
cancer 
dx 
 isotype stage  therapy histology stage  therapy   
F/U 
1  M  72  72    IgG κ  N/A  MP    SCC  N/A  R    Death 3 month after dx due to 
sepsis 
3  M  63 63   IgG  κ  IIIA  –    ADC IV  C/T    N/A 
2  M  51 51   IgG  κ  I  –    SCLC  Limited 
disease 
C/E/R    Death due to brain metastasis 
4 M  67*  67    IgG κ  N/A  –    ADC  IB  C/T (4) 
C/T/V/To 
(5) 
 N/A 
5  M  52 52   IgG  λ  N/A  D    SCC IB  Surgery    F/U  at  clinic 
Our  case  M  78 75   IgG  λ  IIIA  TD    ADC IV  Efitinib 
C/T/B 
 Death  2  weeks 
after MM dx 
MM = Multiple myeloma; dx = diagnosis; MP = mephalan, prednisone; TD = thalidomide, dexamethasone; SCC = squamous cell carcinoma; 
ADC = adenocarcinoma; SCLC = small cell lung cancer; R = radiotherapy; C = carboplatin; T = taxane; E = etoposide; V = vinorelbine; To = 
topotecan; B = bevacizumab; N/A = not available; F/U = follow-up.  
Figures in parentheses represent the number of chemotherapy courses. * 6 months after initial diagnosis of lung cancer. 
 
 
 
 
 
Fig. 1. Right lung nodule (arrow). 
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Fig. 2. Right supraclavicular lymphadenopathy (arrow). 
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